Moderna is set to reveal a collaboration with OpenAI, a leader in artificial intelligence. This partnership aims to streamline nearly all operations within the biotech firm and expand the reach of ChatGPT, the AI platform, into the corporate sector.
Under this agreement, around 3,000 Moderna staff will gain access to ChatGPT Enterprise, powered by OpenAI's cutting-edge language model, GPT-4, by the week's end. By further integrating AI into its workflows, Moderna anticipates accelerating its timeline for introducing 15 new products over the next five years, surpassing its initial projections.
OpenAI's CEO, Sam Altman, emphasised the role of AI in advancing scientific endeavours while highlighting the importance of enhancing human productivity. Moderna aims to extend its focus beyond Covid by leveraging its messenger RNA platform across various domains, from preventing viral diseases to addressing cancer. CEO Stéphane Bancel underscored the significance of the OpenAI partnership in revolutionising all aspects of Moderna's operations.
To date, Moderna employees have developed over 750 customised versions of ChatGPT, tailored to streamline diverse tasks across the company, such as optimising clinical trial doses and drafting regulatory responses.
The adoption of AI holds significant promise for Moderna, which currently relies heavily on its Covid-19 vaccine for revenue. By leveraging AI, the company anticipates expediting the development of new products and maintaining agility in its operations.
Bancel expressed his enthusiasm for ChatGPT, incorporating it into his daily routine and encouraging employees to utilise it frequently.
Among the developed ChatGPT applications, one aids in predicting optimal drug doses for clinical trials, while another expedites the regulatory response process. Additionally, AI is employed in drug manufacturing to forecast enzyme structures for enhanced efficiency.
While the potential of AI in drug discovery has garnered considerable attention, its practical application remains to be fully validated. OpenAI provides ongoing support to Moderna, facilitating regular communication, strategy alignment, and problem-solving.
OpenAI views its partnership with Moderna as exemplary in terms of the scope and maturity of AI integration. Altman aspires to replicate this successful model with other companies, aiming for comprehensive collaboration across all fronts.
Click here to read the original news story.